Portfolio company
Peptomyc
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops cell-penetrating mini-protein therapeutics for the treatment of cancer patients with solid tumours and intends to license these products to pharmaceutical companies.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Pep-Therapy
This biotechnology company develops intracellular peptide-based targeted therapies to treat patients with advanced solid tumours, including pancreatic and ovarian cancers.
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
Cybrexa
The company develops peptide-drug conjugate therapeutics for oncology patients to deliver anti-cancer agents directly into tumours using a pH-sensitive targeting platform.
Cytovation AS
This company develops peptide-based immunotherapy treatments for patients with solid tumours and cancers driven by the Wnt/β-catenin signalling pathway.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Nanoligent
The company develops targeted protein-drug nanoconjugates for oncology patients to treat metastatic tumours by selectively eliminating cells overexpressing the CXCR4 receptor.